Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
NCT ID: NCT02708056
Last Updated: 2016-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
26 participants
INTERVENTIONAL
2015-01-31
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sugammadex Dose Finding Under Two Years Old
NCT06575036
Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates
NCT04566796
Sugammadex: Effect on the Awareness Monitoring and Hemodynamics
NCT01301261
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
NCT05202899
Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children
NCT04347486
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sugammadex, Bridion
Drug were given intravenously by a anesthesiologist at the end of surgery
Sugammadex
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sugammadex
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study
Exclusion Criteria
* hepatic or renal failure
* A history of allergy to study medication
1 Month
12 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baskent University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ozlem Ozmete
Medical Doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KA 16-67
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.